Navigation Links
In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups

X-linked severe combined immunodeficiency (XSCID) is a genetic disorder which completely affects the immune system. In case basset pups which suffered from XSCID in-vivo gene //therapy was successfully used to cure this life threatening disease. The researchers from the University Of Pennsylvania School Of Veterinary Medicine and the National Institute of Allergy and Infectious Disease introduced a retro virus which acts as a vector for the correct gene of XSCID.

The results of their study were presented in the journal Blood. In humans; XSCID affects one in 100,000 boys, resulting from the inheritance of a faulty gene on one of the mother's X-chromosomes. It often proves fatal before the child's first birthday. The disease first came to public attention in the late 1970s with the ‘Bubble Boy,’ David Vetter, who lived his entire life in a sterilized environment in order to protect him from outside germs. Vetter died in 1984. The only treatment for XSCID is through a bone-marrow transplant from a normal donor designed to replenish the hematopoietic stem cells that are capable of constantly renewing new functional immune cells, or, more recently, gene therapy that works by replacing the defective gene with a normal gene in the patients own cells.

Gene therapy has been put to curative use against this disease in humans resulting in successful immune reconstitution in 10 of 11 boys in a 1999 French study. This clinical trial consisted of the standard ex-vivo approach to gene therapy in which bone-marrow cells were taken out of the body of the affected boy, cultured in vitro for five days with exposure to a retroviral vector containing the normal gene and transplanted back into the patient. Three of the boys unfortunately developed a T-cell leukemia attributed to the gene therapy resulting in the cessation of this study. ‘Although ex-vivo gene therapy has been shown to be capable of restoring normal immune function in XSCID boys, there are severa l potential problems with this approach,’ said Peter J. Felsburg, professor of immunology at Penn's School of Veterinary Medicine. ‘The number of gene-corrected bone- marrow stem cells that can be transplanted back into the patient is limited to correcting the potentially low number of bone-marrow stem cells harvested from the patient. In addition, the manipulation and culturing of the cells outside the body may alter their ability to provide for long-term generation of new immune cells.’

The Penn researchers and their NIAID colleagues, led by Drs. Suk See Ting-De Ravin and Harry L. Malech took a different approach by directly injecting the retrovirus vector containing the corrective gene into the bloodstream of XSCID dogs with the hope of correcting the defective hematopoietic stem cells within the patient. The therapy completely restored immune function in three of the four dogs the researchers treated. The fourth dog received the lowest dose of the retrovirus vector the virus that had been engineered to pass on the gene leading Felsburg and his colleagues to believe that there is a lower limit to the dose before the treatment becomes effective. Since the boys involved in the French gene-therapy study did not develop leukemia until more than three years after the treatment began, the researchers have been particularly interested in knowing the long-term consequences of the trial. At 16 and 18 months following treatment, the two dogs involved in the long-term study have maintained their immune systems and remain, effectively, cured of XSCID, with no adverse side effects.

‘The results of this study show that this in-vivo approach to gene therapy may be a viable alternative for not only gene therapy of XSCID but perhaps other hematologic and immunologic diseases, thereby eliminating any potential detrimental effects of the ex-vivo manipulation and culture of cells that is required by current clinical gene therapy protocols,’ Felsburg said. ‘In addition, this approach would make it easier to perform gene therapy outside of specialized medical centers.’ Felsburg's research was funded by grants from the National Institute of Allergy and Infectious Disease of the National Institutes of Health.

Source: Eurkalert
'"/>




Related medicine news :

1. Detecting DNA Damage With In-Vivo Alkaline Comet Assay
2. Cancer Doctors Okays Controversial Prostate Therapy
3. Consensus on "Combination Therapy" for Breast Cancer
4. Gene Therapy shows promise in treating Hemophilia
5. "Make AIDS Therapy affordable" - Physicians demand
6. Hormone replacement Therapy a headache
7. Simple Therapy
8. Therapy for stopping the spread of cancer cells
9. Gene Therapy Destroys Pancreatic Cancer Cells
10. Letrozole Beats Tamoxifen in Breast Cancer Therapy
11. Garlic Supplements Impede HIV Therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies perfectly ... in the company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized ... resources they need to live affordably and abundantly without unduly taxing the resources of ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home ... of Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business ... our agency and our ability to provide quality care to the community,” said Tammara ...
(Date:4/21/2017)... AUGUSTA, GA (PRWEB) , ... April 21, 2017 , ... ... Festival in Augusta, Georgia. , This festival offers entertainment for everyone — from ... Sacred Heart Garden Festival is a very high quality event held in a grand ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology: